NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
SBFM
Sunshine Biopharma, Inc.
There isn't enough reported data to score SBFM yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
SBFM Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Under pressure | |
| Unavailable |
SBFM's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
SBFM PE Valuation
SBFM has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
SBFM Forward outlook
There aren't enough analyst estimates for SBFM to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
SBFM Earnings Per Share
SBFM and NVO do not have enough comparable growth data to identify a winner.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over SBFM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over SBFM on profitability, with a higher operating margin.
SBFM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $9.4M | +0.3% |
| Q2 2026 | $9.3M | -1.6% |
| Q1 2026 | $8.1M | -9.1% |
| Q4 2025 | $8.6M | -11% |
| Q3 2025 | $9.4M | +12% |
| Q2 2025 | $9.4M | +1.2% |
| Q1 2025 | $8.9M | +18% |
| Q4 2024 | $9.6M | +25% |
SBFM's revenue is down over the past year, though its latest quarter was up: $9M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -14% | -2.1 points |
| Q2 2026 | -17% | +4.4 points |
| Q1 2026 | -17% | -2.7 points |
| Q4 2025 | -21% | +0.4 points |
| Q3 2025 | -12% | +1.6 points |
| Q2 2025 | -22% | -8.2 points |
| Q1 2025 | -15% | +3.3 points |
| Q4 2024 | -21% | -5.8 points |
SBFM's operating margin was −14% last quarter, down 2.1 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over SBFM on cash generation, producing positive trailing cash flow while its opponent burns cash.
SBFM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.4M | -$648.2K |
| Q2 2026 | -$925K | +$508.4K |
| Q1 2026 | -$2.1M | -$355.9K |
| Q4 2025 | -$1.6M | +$1.9M |
| Q2 2025 | -$1.4M | +$3.1M |
| Q1 2025 | -$1.7M | +$1.5M |
| Q4 2024 | -$3.5M | -$1.2M |
| Q1 2024 | -$3.2M | -$1.3M |
SBFM has burned cash in almost every quarter: −$6M over the past year, against −$7M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over SBFM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
SBFM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +178% | +43.7K shares |
| 1 year | +279% | +50.2K shares |
SBFM has 68,266 diluted shares, up 279% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
SBFM Net Leverage
SBFM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
SBFM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 19.1 | Oversold |
| Stochastic | 0.9 | Oversold |
SBFM's weekly RSI is 19 (oversold) and its Stochastic is 1 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SBFM PE vs Healthcare Sector
SBFM has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over SBFM on trend strength, trading above more of its moving averages.
SBFM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.61 | 57% below |
| 20 week MA | $19.3 | 85% below |
| 50 week MA | $123.0 | 98% below |
| 100 week MA | $245.6 | 99% below |
| 200 week MA | $59,597.2 | 100% below |
SBFM is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over SBFM on returns for 2026, with the stronger performance.
SBFM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $200,000.0 | $334,000.0 | +67% |
| 2021 | $334,000.0 | $1,298,000.0 | +289% |
| 2022 | $1,298,000.0 | $264,000.0 | -80% |
| 2023 | $264,000.0 | $108,600.0 | -59% |
| 2024 | $108,600.0 | $612.0 | -99% |
| 2025 | $612.0 | $252.0 | -59% |
| 2026 YTD | $252.0 | $2.84 | -99% |
SBFM has finished four years in a row lower, and it's down 99% so far in 2026.